Signet Financial Management LLC Acquires 1,730 Shares of Pfizer Inc. (NYSE:PFE)

Signet Financial Management LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 41,591 shares of the biopharmaceutical company’s stock after purchasing an additional 1,730 shares during the period. Signet Financial Management LLC’s holdings in Pfizer were worth $1,197,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. RB Capital Management LLC grew its holdings in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. grew its holdings in Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares during the last quarter. United Bank grew its holdings in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares during the last quarter. Ergoteles LLC lifted its position in shares of Pfizer by 136.3% in the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp lifted its position in shares of Pfizer by 6.4% in the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Finally, Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Trading Down 0.8 %

Shares of NYSE PFE opened at $25.69 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a market cap of $145.47 billion, a P/E ratio of 71.36, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $41.33. The firm has a 50-day moving average of $27.23 and a 200 day moving average of $28.79.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.